רווח נקי למניה ב-12 החודשים האחרונים: Sionna Therapeutics, Inc. (SION)

Sionna Therapeutics Inc (SION) operates in a high-risk zone, battling biotech behemoths for leadership in cystic fibrosis gene therapy. The company relies on proprietary protein restoration platforms, creating a monopoly barrier for competitors. Anticipation of Phase II small molecule trial results drives the momentum, while the 12-month rolling earnings per share history shows that -2.43 serves as the current metric level.
פילוחים אנליטיים ודוחות נתונים של חברת Sionna Corp (SION)

An investment audit of Sionna Therapeutics Inc (SION) requires an analysis of EPS TTM, calculated as the ratio of annual net income to shares outstanding to assess the actual return on equity. On the GURU.Markets platform, the change in TTM earnings per share reflects the capitalization potential of future monopoly pricing for cystic fibrosis therapies, converting fundamental earnings into market value.